Afayro 30mg Tablet

Afayro 30mg tablet is an ant-cancer medication which is a prescription based medication used to treat non small cell lung cancer (NSCLC). It works by blocking the epidermal growth factor (EGFR) which is involved for the growth and multiplication of cancer cells, thereby helping to slow or stop tumor growth. The active ingredient in the medication is Afatinib, which is a salt form used in the tablet.The medication is used alone as it is a monotherapy medication. Patient should take it exactly as prescribed by the doctor, all medical instructions carefully and report any side effects or unusual symptoms promptly.

Non small cell lung cancer (NSCLC)

Like other medication Afayro 30mg tablet cause various side effects, some may resolve on their own and some need proper medication to relieve the symptoms. Consult the doctor If the symptoms worsen:
● Diarrhea
● Mouth sores
● Acne or skin rash
● Nausea and vomiting
● Fatigue
● Loss of appetite
● Abdominal pain
● Interstitial lung disease (ILD)
● Severe diarrhea or dehydration
● Liver problems
● Eye problems, such as corneal erosion or ulceration

Doctor recommend the correct dosage and duration of Afayro 30mg tablet based on the patient's medical condition and response to the treatment. This tablet should be taken with a whole glass of water, do not crush or chew it take it as it is. Never skip or double the dose without consulting the doctor to ensure safety and effectiveness of the treatment.

Afayro 30g tablet is a targeted therapy which specifically target on the cancer cells that is most commonly those with mutation in the EGFR (epidermal growth factor receptor). The medication block EGFR mutation gene which is the responsible for the growth of cancer cells in the body. It helps prevent the growth and multiplication of tumor cells in the body.

• Wecker, H., & Waller, C. F. (2018). Afatinib. Small Molecules in Oncology, 199-215.
• Dungo, R. T., & Keating, G. M. (2013). Afatinib: first global approval. Drugs, 73(13), 1503-1515.
• Wind, S., Schnell, D., Ebner, T., Freiwald, M., & Stopfer, P. (2017). Clinical pharmacokinetics and pharmacodynamics of afatinib. Clinical pharmacokinetics, 56(3), 235-250.
• Nelson, V., Ziehr, J., Agulnik, M., & Johnson, M. (2013). Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. OncoTargets and therapy, 135-143.
• Keating, G. M. (2014). Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer. Drugs, 74(2), 207-221.